Arvind Sreedharan


Arvind Sreedharan is Vice President of Marketing at Auspex Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's Disease, Tourette Syndrome and Tardive Dyskinesia. Prior to joining Auspex, Arvind served as Director of Movement Disorder Marketing at Lundbeck LLC. At Lundbeck, Arvind played a lead role in the launch and commercialization of XENAZINE, the first FDA approved drug to treat chorea associated with Huntington’s disease. Arvind has held numerous positions in marketing, sales, sales management and training in the pharmacy industry over the last 24 years and has been a strong strategic partner with HDSA national on numerous educational and fundraising initiatives to support the HD community.

Arvind is a graduate of the University of North Carolina with a BA in Biology/History.